(RVMD) Revolution Medicines - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 30.148m USD | Total Return: 269.3% in 12m
Oncology Drugs, RAS Inhibitors, Cancer Therapies
Total Rating 40
Safety 75
Buy Signal 0.10
Biotechnology
Industry Rotation: -4.3
Industry Rotation: -4.3
Market Cap:
30.1B
Avg Turnover: 407M
Avg Turnover: 407M
Risk 3d forecast
Volatility50.2%
VaR 5th Pctl7.41%
VaR vs Median-13.0%
Reward TTM
Sharpe Ratio2.20
Rel. Str. IBD97.8
Rel. Str. Peer Group90.8
Character TTM
Beta1.339
Beta Downside0.487
Hurst Exponent0.533
Drawdowns 3y
Max DD48.63%
CAGR/Max DD1.62
CAGR/Mean DD4.56
Warnings
Interest Coverage Ratio -37.2 is critical
Altman Z'' -8.50 < 1.0 - financial distress zone
Tailwinds
Leader
Description: RVMD Revolution Medicines
Revolution Medicines, Inc. (RVMD) is a Redwood City-based clinical-stage biotechnology company focused on developing targeted therapies for RAS-addicted cancers. The company’s proprietary pipeline centers on RAS(ON) inhibitors, including daraxonrasib (RMC-6236) and zoldonrasib (RMC-9805), which are currently being evaluated in Phase 3 registrational trials for pancreatic ductal adenocarcinoma (PDAC).
The company utilizes a precision oncology business model, targeting specific genetic mutations such as G12C, G12D, and G12V to inhibit tumor growth. This approach is critical as RAS mutations are estimated to drive approximately 30% of all human cancers, historically representing one of the most challenging targets in drug discovery. Analyzing the companys clinical milestones on ValueRay can provide deeper insights into its long-term valuation. Revolution Medicines maintains a diverse portfolio of development candidates, including RMC-5127 and RMC-0708, to address a broad spectrum of solid tumors.
- Clinical data readouts for RMC-6236 drive investor confidence in RAS-addicted cancer treatments
- Phase 3 trial success of daraxonrasib determines long-term commercial viability in PDAC
- Research and development spending levels impact cash runway and future capital requirements
- Regulatory approval timelines for RAS-ON inhibitors dictate the pace of market entry
- Competitive landscape for KRAS inhibitors affects potential market share and pricing power
Piotroski VR‑10 (Strict)
0.0
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.48 > 0.02 and ΔFCF/TA -22.11 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.47 > 3% & CFO -1.06b > Net Income -1.37b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.80 > 1.5 & < 3 |
| Outstanding Shares: last quarter (198.1m) vs 12m ago 5.29% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 11.06%; Δ -11.06% > 0%) |
| Interest Coverage Ratio: -37.21 > 6 (EBITDA TTM -1.34b / Interest Expense TTM 36.5m) |
Altman Z''
-8.50
| A: 0.74 (Total Current Assets 1.97b - Total Current Liabilities 289.6m) / Total Assets 2.25b |
| B: -1.47 (Retained Earnings -3.32b / Total Assets 2.25b) |
| C: -0.59 (EBIT TTM -1.36b / Avg Total Assets 2.31b) |
| D: -4.41 (Book Value of Equity -3.32b / Total Liabilities 753.8m) |
| Altman-Z'' Score: -8.50 = D |
What is the price of RVMD shares?
As of May 16, 2026, the stock is trading at USD 145.66 with a total of 2,475,276 shares traded.
Over the past week, the price has changed by +2.71%, over one month by -4.51%, over three months by +44.78% and over the past year by +269.32%.
Over the past week, the price has changed by +2.71%, over one month by -4.51%, over three months by +44.78% and over the past year by +269.32%.
Is RVMD a buy, sell or hold?
Revolution Medicines has received a consensus analysts rating of 4.67.
Therefore, it is recommended to buy RVMD.
- StrongBuy: 8
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the RVMD price?
| Analysts Target Price | 181.3 | 24.5% |
Revolution Medicines (RVMD) - Fundamental Data Overview
as of 11 May 2026
P/S = 9035.0954 P/B = 20.1085
Revenue TTM = 0.0 USD
EBIT TTM = -1.36b USD
EBITDA TTM = -1.34b USD
Long Term Debt = 158.7m USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 16.6m USD (from shortTermDebt, last quarter)
Debt = 175.3m USD (corrected: LT Debt 158.7m + ST Debt 16.6m)
Net Debt = -1.73b USD (recalculated: Debt 175.3m - CCE 1.91b)
Enterprise Value = 28.42b USD (30.15b + Debt 175.3m - CCE 1.91b)
Interest Coverage Ratio = -37.21 (Ebit TTM -1.36b / Interest Expense TTM 36.5m)
EV/FCF = -26.51x (Enterprise Value 28.42b / FCF TTM -1.07b)
FCF Yield = -3.77% (FCF TTM -1.07b / Enterprise Value 28.42b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 13.0m) / Revenue TTM)
Tobins Q-Ratio = 12.61 (Enterprise Value 28.42b / Total Assets 2.25b)
Interest Expense / Debt = 6.96% (Interest Expense 12.2m / Debt 175.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -1.07b (EBIT -1.36b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.80 (Total Current Assets 1.97b / Total Current Liabilities 289.6m)
Debt / Equity = 0.12 (Debt 175.3m / totalStockholderEquity, last quarter 1.50b)
Debt / EBITDA = 1.29 (negative EBITDA) (Net Debt -1.73b / EBITDA -1.34b)
Debt / FCF = 1.62 (negative FCF - burning cash) (Net Debt -1.73b / FCF TTM -1.07b)
Total Stockholder Equity = 1.65b (last 4 quarters mean from totalStockholderEquity)
RoA = -59.39% (Net Income -1.37b / Total Assets 2.25b)
RoE = -83.22% (Net Income TTM -1.37b / Total Stockholder Equity 1.65b)
RoCE = -75.08% (EBIT -1.36b / Capital Employed (Equity 1.65b + L.T.Debt 158.7m))
RoIC = -63.12% (negative operating profit) (NOPAT -1.07b / Invested Capital 1.70b)
WACC = 10.66% (E(30.15b)/V(30.32b) * Re(10.69%) + D(175.3m)/V(30.32b) * Rd(6.96%) * (1-Tc(0.21)))
Discount Rate = 10.69% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 8.67%
[DCF] Fair Price = unknown (Cash Flow -1.07b)
EPS Correlation: -82.65 | EPS CAGR: -52.44% | SUE: -4.0 | # QB: -6
Revenue Correlation: -40.96 | Revenue CAGR: -8.19% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-2.00 | Chg30d=-5.54% | Revisions=+29% | Analysts=17
EPS next Quarter (2026-09-30): EPS=-1.96 | Chg30d=+1.67% | Revisions=+43% | Analysts=17
EPS current Year (2026-12-31): EPS=-7.96 | Chg30d=-4.66% | Revisions=+41% | GrowthEPS=-33.8% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-5.46 | Chg30d=+18.94% | Revisions=+62% | GrowthEPS=+31.4% | GrowthRev=+767.5%
[Analyst] Revisions Ratio: +62%